Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.71 |
| ▸ | HTR2A | P28223 | 13/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5503981 | 0.92 | SLC6A4 (0.79) | SLC6A4KCNH2SLC6A2HTR2ASLC6A3 | |
| SCHEMBL5497424 | 0.85 | SLC6A4 (0.70) | SLC6A4KCNH2SLC6A2HTR2ASLC6A3 | |
| SCHEMBL5497240 | 0.85 | SLC6A4 (0.69) | SLC6A4KCNH2SLC6A2HTR2ASLC6A3 | |
| SCHEMBL5498722 | 0.84 | SLC6A4 (0.68) | SLC6A4KCNH2SLC6A2HTR2ASLC6A3 | |
| SCHEMBL5507291 | 0.84 | SLC6A4 (0.67) | SLC6A4KCNH2SLC6A2HTR2ASLC6A3 | |
| SCHEMBL5498686 | 0.83 | SLC6A4 (0.66) | SLC6A4KCNH2SLC6A2HTR2ASLC6A3 | |
| SCHEMBL5503312 | 0.83 | SLC6A4 (0.66) | SLC6A4KCNH2SLC6A2HTR2ASLC6A3 | |
| SCHEMBL5501094 | 0.82 | SLC6A4 (0.48) | SLC6A4KCNH2SLC6A2HTR2ASLC6A3 | |
| SCHEMBL5502807 | 0.82 | SLC6A4 (0.69) | SLC6A4KCNH2SLC6A2HTR2ASLC6A3 | |
| SCHEMBL5498330 | 0.80 | SLC6A4 (0.62) | SLC6A4KCNH2SLC6A2HTR2ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | claimed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | claimed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | claimed |
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | SLC6A4 150/4885KCNH2 2331/4885SLC6A2 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.